Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults

The Federal Guidelines on preventive vaccination against pneumococcal infections in adults were developed by experts of Russian Respiratory Society and National Non-profit Association of Specialists for Control Healthcare-Associated Infections. Studies published during the previous 5 years were selected from EMBASE, MEDLINE, and PubMed databases andthe Cochrane library and were reviewed by independent experts with consideration of practical physicians’ opinions. The results of this analysis underlay the guidelines. Quality of evidence and strength of recommendations were assessed according to widespread criteria. The guidelines include epidemiology, social burden, pathogenesis, and clinical course of pneumococcal infections, characteristic of vaccines used to prevent pneumococcal infections and special considerations of preventive vaccination in patients with comorbidity and in risk groups. The experts discussed efficacy of preventive vaccination and postvaccinal reactions. The guidelines meet the requirements of Healthcare Ministry of Russian Federation.

1. Briko N.I., ed. [Epidemiology, Clinics, and Prevention of Pneumococcal Infection. A Study Guide for Physicians]. Nizhniy Novgorod: Remedium Privolzh'e; 2017 (in Russian).

2. Tatochenko V.K., Ozeretskovskiy N.A. [Preventive Immunization. 2018. A Manual]. The 13th Revised Edition. Moscow: Borges; 2018 (in Russian).

3. Pollard A.J., Perrett K.P., Beverley P.C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 2009; 9 (3): 213–220. DOI: 10.1038/nri2494.

4. Caplan A., Fett N., Rosenbach M. et al. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Infectious complications and vaccination recommendations. J. Am. Acad. Dermatol. 2017; 76 (2): 191–198. DOI: 10.1016/j.jaad.2016.02.1240.

5. Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 2009; 9 (3): 185–194. DOI: 10.1038/nri2508.

6. Huijts S.M., van Werkhoven C.H., Bolkenbaas M. et al. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine. 2017; 35 (34): 4444–4449. DOI: 10.1016/j.vaccine.2017.01.071.

7. Shea K.M., Edelsberg J., Weycker D. et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect. Dis. 2014; 1 (1): ofu024. DOI: 10.1093/ofid/ofu024.

8. Luján M., Burgos J., Gallego M. et al. Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies. Clin. Infect. Dis. 2013; 57 (12): 1722–1730. DOI: 10.1093/cid/cit640.

9. Kostinov M.P., Chuchalin A.G., ed. [A Handbook on Clinical Immunology in Respiratory Medicine]. The 2nd Revised Edition. Moscow: MDV; 2018 (in Russian).

10. Koch D.H., Moon K.T., Kim J.Y. et al. The risk of hospitalization for infectious pneumonia in mineral dust exposed industries. Occup. Environ. Med. 2011; 68 (2): 116–119. DOI: 10.1136/oem.2009.051334.

11. Coggon D., Harris E.C., Cox V., Palmer K.T. Pneumococcal vaccination for welders. Thorax. 2015; 70 (2): 198–199. DOI: 10.1136/thoraxjnl-2014-206129.

12. Lobzin Y.V., Sidorenko S.V., Kharit S.M. et al. [Streptococcus pneumoniae serotypes causing major pneumococcal infections]. Zhurnal infektologii. 2013; 5 (4): 36–42 (in Russian).

13. Beloshitskiy G.V., Korolyova I.S., Mironov K.O. [Phenotypic and genotypic characteristics of pneumococci isolated from patients with pneumococcal meningitis]. Klinitcheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2011; 13 (3): 261–266 (in Russian).

14. Siegrist C.A. Vaccine immunology. In: Plotkin S.A., Orenstein W.A., Offit P.A., eds. Vaccines. The 6th Edition. Philadelphia: Elsevier-Saunders; 2013.

15. Bonten M.J.M., Huijts S.M., Bolkenbaas M. et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N. Eng. J. Med. 2015; 372: 1114–1125. DOI: 10.1056/NEJMoa1408544.

16. Falkenhorst G., Remschmidt C., Harder T. et al. [Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016; 59 (12): 1623–1657. DOI: 10.1007/s00103-016-2466-9 (in German).

17. Gonzalez-Romo F., Picazo J.J. Rojas A.G. et al. [Consensus document on pneumococcal vaccination in adults at risk by age and underlying clinical conditions. 2017 Update]. Rev. Esp. Quimioter. 2017; 30 (2): 142–168. Available at:http://www.seq.es/seq/0214-3429/30/2/gonzalez15feb2017.pdf (in Spanish).

18. Australian Government Department of Health. Australian Immunisation Handbook. The National Immunisation Program. Available at: http://www.health.gov.au/internet/immunise/publishing.nsf/Content/national-immunisation-program-schedule

19. Center for Disease Control and Prevention. Pneumococcal Diseases. Pneumococcal Vaccination. Available at: https://www.cdc.gov/pneumococcal/vaccination.html

20. Tin Tin Htar M., Stuurman A.L., Ferreira G. et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS One. 2017; 12 (5): e0177985. DOI: 10.1371/journal.pone.0177985.

21. Center for Disease Control and Prevention. Vaccine Recommendations and Guidelines of the ACIP. Available at: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html

22. van Cuyck H., Pichon B., Leroy P. et al. Multiple-locus variable-number tandem-repeat analysis of Streptococcus pneumoniae and comparison with multiple loci sequence typing. BMC Microbiology. 2012; 12: 241. DOI: 10.1186/1471-2180-12-241.

23. Martynova A.V., Balabanova L.A., Chulakova O.A., Sheparev A.A. [Molecular epidemiological monitoring of Streptococcus pneumoniae strains isolated from elderly patients with community-acquired pneumonia]. STM. 2014; 6 (3): 91–96. Available at: https://cyberleninka.ru/article/v/molekulyarno-epidemiologicheskiy-monitoring-shtammov-streptococcus-pneumoniae-vydelennyh-u-patsientov-pozhilogo-vozrasta-s (in Russian).

24. Demko I.V., Korchagin E.E., Gordeeva N.V. et al. [An experience of vaccination against pneumococcal infection of adults at Krasnoyarsk krai]. Pul'monologiya. 2017; 27 (1): 21–28. DOI: 10.18093/0869-0189-2017-27-1-21-28 (in Russian).

25. Zakharova I.A. [Possibilities to prevent acute exacerbations of chronic bronchitis in young patients]. Sovremennye problemy nauki i obrazovaniya. 2016; 5 (in Russian).

26. Ignatova G.L., Antonov V.N. [Epidemiological characteristics of chronic respiratory diseases in patients vaccinated against pneumococcal infection]. Pul'monologiya. 2017; 27 (3): 376–383. DOI: 10.18093/0869-0189-2017-27-3-376-383 (in Russian).

27. Ignatova G.L., Antonov V.N. [Efficacy of preventive vaccination against pneumococcal infection in patients with chronic obstructive pulmonary disease and comorbidity]. Epidemiologiya i vaktsinoprofilaktika. 2017; 16 (5): 22–27. DOI: 10.31631/2073-3046-2017-16-5-22-27 (in Russian).

28. Clinical Guidelines. Chronic Heart Failure. A Society of Specialists on Heart Failure. Russian Society of Cardiologists. Available at: www.ossn.ru/upload/medialibrary/003/РекомендацииОССН_МЗ_30012017.pdf (in Russian).

29. Protasov A.D., Zhestkov A.V., Kostinov M.P. et al. [An analysis of long-term efficacy and adaptive immunity development under the use of different vaccines and vaccination schemes against pneumococcal infection in patients with chronic obstructive pulmonary disease]. Terapevticheskiy arkhiv. 2017; 89 (12-2): 165–174 (in Russian).

30. Golodnova S.O., Fel’dblyum I.V., Semerikov V.V. et al. [The prevalence of Streptococcus pneumoniae carriage and evaluation of preventive vaccination in healthcare workers]. Epidemiologiya i vaktsinoprofilaktika. 2014; 1 (74): 50–54 (in Russian).

31. Fel'dblyum I.V., Nikolenko V.V., Vorob'eva N.N. et al. [Reactogenicity, safety, immunogenicity and efficacy of polysaccharide pneumococcal vaccine in HIV-infected patients]. Zhurnal mikrobiologii, epidemiologii, immunobiologii. 2013; (3): 52–60 (in Russian).

32. Nikolenko V.V., Fel’dblyum I.V., Golodnova S.O., Vorobiova N.N. [Healthcare workers as a high-risk group for pneumococcal infection]. Meditsinskiy al'manakh. 2014; 4 (34): 30–34 (in Russian).

33. Chuchalin A.G., Onishchenko G.G., Kolosov V.P. et al. [Anti-epidemic measured for prevention of pneumococcal infections in flooded areas of the Amur region]. Pul'monologiya. 2015; 25 (3): 303–311. DOI: 10.18093/0869-0189-2015-25-3-303-311 (in Russian).

34. Rubin L.G., Levin M.J., Ljungman P. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin. Infect. Dis. 2014; 58 (3): 309–318. DOI: 10.1093/cid/cit816.

35. U.S. National Library of Medicine. Pneumococcal Vaccine in Untreated CLL (Chronic Lymphocytic Leukemia) Patients. ClinicalTrials . gov NCT01892618. Available at: https://clinicaltrials.gov/ct2/show/NCT01892618?term=NCT01892618&rank=1

36. U.S. National Library of Medicine. VACcination In Methotrexate Treated Rheumatoid Arthritis Patients (VACIMRA). ClinicalTrials . gov NCT01942174. Available at: https://clinicaltrials.gov/ct2/show/NCT01942174?term=NCT01942174&rank=1

37. McLaughlin J.M., Jiang Q., Isturiz R.E. et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: A test-negative design. Clin. Infect. Dis. 2018; 67 (10): 1498–1506. DOI: 10.1093/cid/ciy312.

38. Greenberg R.N., Gurtman A., Frenck R.W. et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60–64 years of age. Vaccine. 2014; 32 (20): 2364–2374. DOI: 10.1016/j.vaccine.2014.02.002.

39. Paradiso P.R. Pneumococcal conjugate vaccine for adults: a new paradigm. Clin. Infect. Dis. 2012; 55 (2): 259–264. DOI: 10.1093/cid/cis359.

40. U.S. National Library of Medicine. Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029). ClinicalTrials . gov NCT02225587. August 26, 2014. Available at: https://clinicaltrials.gov/ct2/results?cond=&term=NCT02225587&cntry=&state=&city=&dist=